10-K: Nascent Biotech Reports Full Year 2024 Results, Advances Pritumumab Clinical Development

Nascent Biotech, a clinical-stage biopharmaceutical company, reported its full-year 2024 results, highlighting progress in its Pritumumab clinical trials and financial position.

Summary

• Nascent Biotech is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for cancer treatment, primarily brain and pancreatic cancers.
• The company's lead drug candidate, Pritumumab, targets ectodomain vimentin, a novel antigen present in various tumor types.
• Nascent completed Phase 1 clinical trials for Pritumumab and received clearance to begin Phase 2 trials.
• The company regained worldwide rights for Pritumumab after mutually ending a license agreement with BioRay Pharmaceutical Co LTD.
• For the year ended March 31, 2024, Nascent reported a net loss of $2,087,682, compared to a net loss of $2,800,969 in the previous year.
• Operating expenses for the year were $2,229,879, including research and development, clinical trials, and consulting costs.
• The company had cash of $372,120 and a negative working capital of $256,674 as of March 31, 2024.
• Nascent plans to commence Phase II clinical trials in the United States in the fourth calendar quarter of 2024.
• The company anticipates needing an additional $15 million to complete Phase 2 trials and prepare for Phase 3.

Sentiment

Score: 4

Explanation: The document highlights positive clinical progress and regaining of rights to Pritumumab, but is overshadowed by significant financial challenges, including operating losses, negative working capital, and a going concern warning. The need for a substantial capital raise also adds uncertainty.

Positives

• The company has completed Phase 1 clinical trials with positive safety outcomes and promising therapeutic signaling.
• Nascent has re-engineered antibody production into the commonly used CHO cell expression system.
• The company has been awarded Orphan Drug Designation for Pritumumab in gliomas and pancreatic cancer.
• The company has regained worldwide rights for Pritumumab, providing full control over its development and commercialization.
• The net loss decreased year-over-year, indicating improved financial management.
• The company has secured patents for enhanced drug delivery to the brain and kits for treating vimentin-expressing tumors.

Negatives

• The company has a history of operating losses and no product revenues.
• Nascent has a negative working capital of $256,674 as of March 31, 2024.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company relies on third-party manufacturers and service providers, which could pose supply chain risks.
• The company has identified a material weakness in its internal control over financial reporting.
• The company is dependent on raising additional capital to fund its operations and clinical trials.

Risks

• The company has a limited operating history and is not profitable.
• The company needs to raise additional capital to fund its operations and clinical trials.
• The company's stock price may be volatile.
• The company's products may face intense competition from other pharmaceutical and biotechnology companies.
• The company's intellectual property may be challenged or circumvented.
• The company's clinical trials may not be successful.
• The company's products may be subject to product liability claims.
• The company's internal controls over financial reporting are not effective.
• The company is dependent on key personnel, and their departure could affect the company's operations.

Future Outlook

The company expects to commence Phase II clinical trials in the United States in the fourth calendar quarter of 2024 and continue to evaluate Pritumumab for other cancer types. They anticipate needing an additional $15 million to complete Phase 2 trials and prepare for Phase 3.

Management Comments

• Management believes that Pritumumab may offer an advantage over existing treatments for brain cancer.
• Management is focused on developing Pritumumab for the treatment of patients with primary brain tumors.
• Management intends to evaluate several options for commercialization, including joint marketing partnerships and out-licensing.

Industry Context

The development of new cancer treatments is highly competitive, with significant resources invested in research and development. Nascent Biotech is competing with major pharmaceutical, biotechnology, and specialty cancer companies, as well as academic institutions and governmental agencies.

Comparison to Industry Standards

• The company's focus on a novel target, ectodomain vimentin, differentiates it from many competitors.
• The company's approach of using a fully human antibody aims to reduce toxicity compared to traditional chemotherapies.
• The company's Phase I trial results showed promising safety outcomes, which is a positive sign compared to other early-stage trials.
• The company's need for $15 million to complete Phase 2 trials is typical for a company at this stage of development.
• The company's negative working capital and going concern warning are not uncommon for early-stage biotech companies.

Related Party Transactions

• The company issued shares of common stock to officers and directors equaling 18% of the outstanding shares of the Company as additional future shares are issued.
• The company issued 7,186,387 shares of common stock with a value of $773,241 to three related parties for service during the year ended March 31, 2024.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential future equity issuances.
• Employees may be impacted by the company's financial instability and potential need to scale back operations.
• Patients may benefit from the development of Pritumumab if it proves to be an effective treatment.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to commence Phase II clinical trials in the United States in the fourth calendar quarter of 2024.
• The company will continue to evaluate the application of Pritumumab in the treatment of other unmet ectodomain vimentin positive cancer types such as pancreatic.
• The company will seek additional financing to fund its operations and clinical trials.

Key Dates

Keywords

Pritumumab, brain cancer, pancreatic cancer, monoclonal antibody, clinical trials, biopharmaceutical, ectodomain vimentin, orphan drug designation, Phase II, oncology